Stay updated on Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe record describes a completed Phase I/II study of pembrolizumab for relapsed or refractory CD19+ lymphomas after CAR T-cell therapy, including eligibility criteria, study design, outcomes, and study documents.SummaryDifference44%

- Check17 days agoChange DetectedThe ClinicalTrials.gov page’s footer revision changed from v3.7.2 to v3.8.0. The displayed study record remains a 403 Forbidden page.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice announces updates to NIH websites and says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now renders a 403 Forbidden error page instead of showing the study record details. Access to the study information is blocked, leaving only site chrome and footer visible.SummaryDifference18%

Stay in the know with updates to Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.